Aardvark Therapeutics to Present at Upcoming Investor Conferences in November

Core Insights - Aardvark Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small-molecule therapeutics aimed at activating innate homeostatic pathways for metabolic diseases [1][2] - The company will present at two upcoming conferences in November, with live webcasts available on its website [1][4] Company Overview - Aardvark is developing therapeutics designed to suppress hunger, particularly for the treatment of Prader-Willi Syndrome (PWS) and other metabolic diseases [2] - The lead compound, ARD-101, is in Phase 3 clinical development for hyperphagia associated with PWS, characterized by insatiable hunger [2] - Aardvark is also working on ARD-201, a fixed-dose combination of ARD-101 with a DPP-4 inhibitor, to address limitations of current GLP-1 therapies for obesity [2]